Virbac (CHIX:VIRPP) Selling, General, & Admin. Expense: €0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:VIRPP Virbac SA CHIX:VIRPP
95 GF Score
Price €344.00
GF Value €368.81
! 2 Warning Signs
View Full Analysis

What is Virbac Selling, General, & Admin. Expense?

Virbac CHIX:VIRPP 95 Selling, General, & Admin. Expense is €0 Mil as of Dec. 2025. GuruFocus rates CHIX:VIRPP with a GF Score™ of 95/100 and a GF Value™ of €368.81. The stock has 2 warning signs investors should review.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Virbac's selling, general, & admin. expense for the six months ended in Dec. 2025 was €0 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2025 was €0 Mil.


Virbac  (CHIX:VIRPp) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Virbac Selling, General, & Admin. Expense Related Terms


Virbac Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Virbac's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Selling, General, & Admin. Expense Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Selling, General, & Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 203.47 0.00 0.00 0.00 0.00

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CHIX:VIRPP vs LLY, JNJ, ABBV: Selling, General, & Admin. Expense Comparison

For the Drug Manufacturers - General subindustry, Virbac's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Virbac Selling, General, & Admin. Expense vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Virbac's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Virbac's Selling, General, & Admin. Expense falls into.


CHIX:VIRPP
95GF Score
Virbac SA CHIX:VIRPP
Selling, General, & Admin. Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of €0 Mil mean?
Virbac (CHIX:VIRPP) has a Selling, General, & Admin. Expense of €0 Mil as of Dec. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Virbac and its competitors.
Is Virbac's Selling, General, & Admin. Expense too high?
Virbac's current Selling, General, & Admin. Expense is €0 Mil. Overall, Virbac has a GF Score™ of 95/100, reflecting its overall financial health beyond just this single metric.
How does Virbac's Selling, General, & Admin. Expense compare to LLY and JNJ?
Virbac's Selling, General, & Admin. Expense of €0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Drug Manufacturers company?
A good Selling, General, & Admin. Expense depends on the Drug Manufacturers industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Virbac and its competitors. Virbac's current Selling, General, & Admin. Expense is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Virbac (CHIX:VIRPP) has a current Selling, General, & Admin. Expense of €0 Mil. The stock's GF Value™ is €368.81, compared to a current price of €344.00 — trading 6.7% below its estimated fair value. The current Selling, General, & Admin. Expense is €0 Mil. Virbac's overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Virbac (CHIX:VIRPP), the current Selling, General, & Admin. Expense is €0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (CHIX:VIRPP) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €344.00 is trading 6.7% below its estimated GF Value™ of €368.81.

Key valuation signals for CHIX:VIRPP:

  • Selling, General, & Admin. Expense: €0 Mil
  • GF Value™: €368.81 vs. price of €344.00 (6.7% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the CHIX:VIRPP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
95GF Score

Get the complete analysis for CHIX:VIRPP

Selling, General, & Admin. Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€344.00
Price
€368.81
GF Value